Frontiers in Pediatrics (Dec 2022)

Parents' dilemma: A therapeutic decision for children with spinal muscular atrophy (SMA) type 1

  • Sophie Boursange,
  • Sophie Boursange,
  • Sophie Boursange,
  • Marco Araneda,
  • Caroline Stalens,
  • Isabelle Desguerre,
  • Isabelle Desguerre,
  • Isabelle Desguerre,
  • Christine Barnerias,
  • Christine Barnerias,
  • Christine Barnerias,
  • Marie-Christine Nougues,
  • Marie-Christine Nougues,
  • Marie-Christine Nougues,
  • Arnaud Isapof,
  • Arnaud Isapof,
  • Arnaud Isapof,
  • Susana Quijano-Roy,
  • Susana Quijano-Roy,
  • Susana Quijano-Roy,
  • Nadia Blu Genestine,
  • Laetitia Ouillade,
  • Maripaz Martinez Jalilie,
  • Claudia Castiglioni,
  • Odile Boespflug-Tanguy,
  • Odile Boespflug-Tanguy,
  • Odile Boespflug-Tanguy,
  • Odile Boespflug-Tanguy,
  • Marcela Gargiulo,
  • Marcela Gargiulo,
  • The SMAPAR Study Group

DOI
https://doi.org/10.3389/fped.2022.1062390
Journal volume & issue
Vol. 10

Abstract

Read online

BackgroundSMA type 1 is a severe neurodegenerative disorder that, in the absence of curative treatment, leads to death before 1 year of age without ventilatory support. Three innovative therapies are available to increase life expectancy.Purpose(i) To increase knowledge about parents' experiences with their decision to have opted for an innovative therapy; (ii) to assess the middle-term psychological consequences in the parents' lives.MethodsWe used an in-depth interview; a self-administrated questionnaire and self-report scales (BDI-II, STAI-Y, PSI-SF, SOC-13, PBA, DAS 16 and FICD). We compared parents hesitant before the decision to parents who were not-hesitant and the group of parents whose child was treated with gene therapy (GT) to parents whose child received another innovative therapy.Main resultsWe included n = 18 parents of 13 children. Parent's mean age was 34.7 (±5.2), child's average age was 44.3 months (±38.0). Retrospectively, most parents felt involved by doctors in decision-making on treatment, they felt their point of view was considered and were satisfied with the effects of the treatment. The group of parents “non-hesitant” was more depressed (p < 0.001), more anxious (p = 0.022) and had higher parental stress (p = 0.026) than the group of “hesitant” parents; the group of “GT-treated” parents was more depressed (p = 0.036) than the group of parents with “other therapy”. Qualitative data highlights revealed: the need to save the child's life at all costs; the fear of coping with end of life and palliative care, the high value of perceived physician confidence in the treatment, the hope that the child will acquire autonomy or be cured. At the time of the decision, no parents felt they fully understood all of the issues regarding therapy and the disease.ConclusionHesitating before making a decision did not predispose parents to depression and anxiety. The narratives suggest that the parents faced a dilemma regarding their child's health in an urgent context. The decision was not final, and parents will continue to think about it throughout the care process.

Keywords